Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 12/2009

01-10-2009 | Letter to the Editors

Early onset neutropenia after mycophenolate mofetil in systemic sclerosis

Authors: Giovanna Cuomo, Giuseppina Abignano, Gabriele Valentini

Published in: Rheumatology International | Issue 12/2009

Login to get access

Excerpt

Mycophenolate mofetil (MMF), by inhibiting the de novo synthesis of purines, displays potent immunosuppressive properties on B and T lymphocytes and is now widely used in transplant medicine [1, 2] and lupus nephritis [3, 4]. Moreover, MMF inhibits the proliferation of vascular smooth muscle cells [5] and fibroblasts [6], thereby suggesting that the drug might be effective in diseases such a scleroderma [7‐9], in which fibrotic process are prominent. …
Literature
1.
2.
3.
4.
5.
6.
7.
8.
9.
Vanthuyne M, Blockmans D, Westhovens R et al (2007) A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25:287–292PubMed
10.
Metadata
Title
Early onset neutropenia after mycophenolate mofetil in systemic sclerosis
Authors
Giovanna Cuomo
Giuseppina Abignano
Gabriele Valentini
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0879-6

Other articles of this Issue 12/2009

Rheumatology International 12/2009 Go to the issue

Original Article

IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system

Original Article

The expression of PADI4 in synovium of rheumatoid arthritis

Original Article

Differences between the early and advanced stages of rheumatoid arthritis in the expression of EDA-containing fibronectin

Original Article

Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India

Original Article

Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis

Original Article

Serum homocysteine level in patients with ankylosing spondylitis

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits